Description

Novartis AG is a global pharmaceutical company dedicated to the discovery, development, production, and commercialization of a broad spectrum of healthcare solutions. Its business operations are segmented into two primary divisions: Innovative Medicines and Sandoz. The Innovative Medicines segment concentrates on delivering prescription medications to both patients and medical professionals. This division's extensive product portfolio addresses various therapeutic areas, including ophthalmology, neurological disorders, immunological conditions, liver diseases, dermatological ailments, respiratory illnesses, cardiovascular health, renal conditions, and metabolic imbalances. Conversely, the Sandoz division specializes in the development, manufacturing, and marketing of finished generic medications. It also supplies active pharmaceutical ingredients (APIs), including antibiotics and other intermediates, along with complete small-molecule pharmaceutical products to external companies. This segment's offerings further encompass retail generics, anti-infective treatments, and biotechnology-derived products such as biosimilars, in addition to providing specialized biotechnology manufacturing services. In terms of strategic alliances, Novartis AG maintains a licensing and collaborative agreement with Alnylam Pharmaceuticals for the development, production, and market introduction of inclisiran. Furthermore, the company is engaged in a clinical partnership with Kura Oncology, Inc., focused on evaluating the combined effectiveness of Tipifarnib and Alpelisib in individuals suffering from head and neck squamous cell carcinoma. Established in 1996, the corporation maintains its headquarters in Basel, Switzerland.